Monoclonal Antibody to Ofloxacin (OFX)
Floxin; Ocuflox
- Product No.MAK753Ge21
- Organism SpeciesPan-species (General) Same name, Different species.
- SourceMonoclonal antibody preparation
- HostMouse
- Potency (Clone Number)C2
- Ig Isotype IgG1 Kappa
- PurificationProtein A + Protein G affinity chromatography
- LabelNone
- Immunogen CPK753Ge21-OVA Conjugated Ofloxacin (OFX)
- Buffer Formulation0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
- TraitsLiquid
- Concentration1mg/mL
- Organism Species Moren/a
- ApplicationsWB; IHC; ICC; IP.
If the antibody is used in flow cytometry, please check FCM antibodies. - DownloadInstruction Manual
- UOM 20µl100µl 200µl 1ml 10ml
- FOB
US$ 119
For more details, please contact local distributors! US$ 279 US$ 398 US$ 995 US$ 3980
SPECIFITY
The antibody is a mouse monoclonal antibody raised against OFX. It has been selected for its ability to recognize OFX in immunohistochemical staining and western blotting.
USAGE
Immunohistochemistry: 5-20µg/mL;
Immunocytochemistry: 5-20µg/mL;
Optimal working dilutions must be determined by end user.
STORAGE
Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
GIVEAWAYS
INCREMENT SERVICES
Catalog No. | Related products for research use of Pan-species (General) Organism species | Applications (RESEARCH USE ONLY!) |
CPK753Ge11 | BSA Conjugated Ofloxacin (OFX) | Immunogen; SDS-PAGE; WB. |
CPK753Ge21 | OVA Conjugated Ofloxacin (OFX) | Immunogen; SDS-PAGE; WB. |
MAK753Ge21 | Monoclonal Antibody to Ofloxacin (OFX) | WB; IHC; ICC; IP. |
MAK753Ge28 | Monoclonal Antibody to Ofloxacin (OFX) | WB; IHC; ICC; IP. |